Engineering Papers⌕ Search

Engineering topics

Grindeland, R. E.

Publications and source records attributed to Grindeland, R. E..

47 records · Page 3
All sourcesNASA NTRSDOE OSTI
NASA NTRS1985

Osteocalcin as an indicator of bone metabolism during spaceflight

The effect of microgravity on osteocalcin (OC) is investigated in rats flown on Spacelab 3. Serum, Ca, Pi, total protein, alkaline phosphatase, and OC contents, and the breaking strength of the humerus of control and Spacelab rats are calculated; the procedures utilized for these analyses are described. It is detected that the OC is reduced, and the serum and alkaline phosphatase are unaffected by microgravity.

Patterson-Buckendahl, P. E.↗
NASA NTRS1985

Ames Research Center life sciences payload - Overview of results of a spaceflight of 24 rats and 2 monkeys

Engineering and biological data gathered with the research animal holding facilities (RAHFs) used on the Spacelab 3 mission are summarized. The animals totaled 24 rats and two squirrel monkeys. The RAHFs included biotelemetry, cameras and environmental monitoring equipment. The primary mission goal was engineering evaluation of the RAHFs and ancillary equipment. Tightly-fitted seals were found to be a necessity for keeping waste and food particles from contaminating the Spacelab equipment. All the rats returned with little muscle tone and suppressed immune systems. The monkeys displayed highly individual responses to spaceflight. Both species exhibited reduced abilities to maintain meticulously clean furs in weightlessness. Details of several physiological changes detected during post-flight autopsies are provided.

Callahan, P. X.↗
NASA NTRS1982

A specific radioimmunoassay for osteocalcin with advantageous species crossreactivity

The specificities of immunoassays to rat and bovine osteocalcin are examined. Extracts of noncalcified tissues and tissue fractions are unreactive to the antibody, with the exception of the kidney, in which the reactive component appears to be identical with osteocalcin by gel filtration and dose dilution analysis. The assays, developed against protein isolated from bone, are also demonstrated to be reactive to the native protein (bone in situ) and to osteocalcin in serum. The assays are sensitive to less than 50 pg osteocalcin. Intra- and interassay coefficients of variation are less than 6.8%. The bovine antibody crossreacts with human, horse, monkey, baboon, and cat osteocalcin, while the rat antibody crossreacts with dog and mouse.

Patterson-Allen, P.↗
NASA NTRS1978

Studies on the bioassayable growth hormone-like activity of plasma

Evidence supporting the existence of bioassayable growth hormone-like activity in blood plasma distinct from the growth hormone measurable by radioimmunoassay and from somatomedin is presented. Tibial assays of the growth-hormone-like activity of injected, concentrated normal human and rat plasma in hypophysectomized rats reveal 200- and 50-fold activity excesses, respectively, with respect to the amount of growth hormone detected by radioimmunoassay. The origin of this bioassayable plasma hormone has been localized to the region of the pituitary, the origin of growth hormone, a distribution not followed by somatomedin C. Purification of the bioassayable agent indicates that is has a molecular weight of between 60,000 and 80,000, in contrast to that of growth hormone (20,000), and that the bioassayable activity is distinct from that of somatomedin C. Growth hormone-like activity detected in Cohn fraction IV as well as plasma activity, are found to be collectable on Dowex 50 resin, in contrast to somatomedin C and nonsuppressible insulin-like activity. The formation of bioassayable growth hormone-activity agents from radioimmunoassayable growth hormone and directly in the pituitary is suggested.

Ellis, S.↗
NASA NTRS1976

Studies on the nature of plasma growth hormone

The paper presents further evidence for the existence of two discrete forms of growth hormone in human plasma, one which is detectable by both radioimmunoassay and bioassay and is immunoreactive, and the other, termed 'bioactive', which is detected by tibial bioassay but shows little reactivity with currently available antisera to pituitary growth hormone. The same division of immunoactive and bioactive growth hormone occurs in rats, though with less disparity. Tests on rats indicated that the bioactive hormone is preferentially released into jugular vein plasma and that plasma concentrations of the bioactive hormone can be enhanced by insulin administration. The bioactive hormone was detectable by tibial assays in Cohn fractions IV, IV-1, and IV-4, and could be concentrated about 40-fold by fractionation with (NaPO3)6 and (NH4)2SO4.

Ellis, S.↗
NASA NTRS1974

Induction of chronic growth hormone deficiency by anti-GH serum

The observations reported indicate that the growth rate of neonatal rats can be specifically inhibited for at least 78 days following the administration of antisera against growth hormone (GH) for only four days after birth. The inhibition can be correlated with a marked deficit of tibial growth promoting activity in the pituitary but not with the plasma concentrations of immuno-reactive GH.

Grindeland, R. E.↗